The DEA recently released a temporary rule extending COVID-19 telehealth flexibilities for the prescription of controlled substances. Per the rule, the DEA states:
- The full set of telemedicine flexibilities regarding prescription of controlled medications as were in place during the COVID-19 PHE will remain in place through November 11, 2023.
- If a patient and a provider establish a telemedicine relationship on or before November 11, 2023, the same telemedicine flexibilities that have governed the relationship to that point regarding the prescription of controlled substances are permitted until November 11, 2024.
Read the DEA press release related to the rule.
%20(1).jpg)
